208 related articles for article (PubMed ID: 31874280)
21. Rationale for the use of alendronate in osteoporosis.
Kanis JA; Gertz BJ; Singer F; Ortolani S
Osteoporos Int; 1995 Jan; 5(1):1-13. PubMed ID: 7703618
[TBL] [Abstract][Full Text] [Related]
22. The effect of nitrogen containing bisphosphonates, zoledronate and alendronate, on the production of pro-angiogenic factors by osteoblastic cells.
Ishtiaq S; Edwards S; Sankaralingam A; Evans BA; Elford C; Frost ML; Fogelman I; Hampson G
Cytokine; 2015 Feb; 71(2):154-60. PubMed ID: 25461393
[TBL] [Abstract][Full Text] [Related]
23. Bisphosphonates: from the laboratory to the clinic and back again.
Russell RG; Rogers MJ
Bone; 1999 Jul; 25(1):97-106. PubMed ID: 10423031
[TBL] [Abstract][Full Text] [Related]
24. Harnessing Nanomedicine to Potentiate the Chemo-Immunotherapeutic Effects of Doxorubicin and Alendronate Co-Encapsulated in Pegylated Liposomes.
Gabizon A; Shmeeda H; Draper B; Parente-Pereira A; Maher J; Carrascal-Miniño A; de Rosales RTM; La-Beck NM
Pharmaceutics; 2023 Nov; 15(11):. PubMed ID: 38004584
[TBL] [Abstract][Full Text] [Related]
25. Risedronate: a new oral bisphosphonate.
Umland EM; Boyce EG
Clin Ther; 2001 Sep; 23(9):1409-21. PubMed ID: 11589256
[TBL] [Abstract][Full Text] [Related]
26. Bisphosphonates-much more than only drugs for bone diseases.
Kuźnik A; Październiok-Holewa A; Jewula P; Kuźnik N
Eur J Pharmacol; 2020 Jan; 866():172773. PubMed ID: 31705903
[TBL] [Abstract][Full Text] [Related]
27. Last generation of amino-bisphosphonates (N-BPs) and cancer angio-genesis: a new role for these drugs?
Santini D; Schiavon G; Angeletti S; Vincenzi B; Gasparro S; Grilli C; La Cesa A; Virzí V; Leoni V; Budillon A; Addeo SR; Caraglia M; Dicuonzo G; Tonini G
Recent Pat Anticancer Drug Discov; 2006 Nov; 1(3):383-96. PubMed ID: 18221048
[TBL] [Abstract][Full Text] [Related]
28. Growth inhibition of macrophage-like and other cell types by liposome-encapsulated, calcium-bound, and free bisphosphonates in vitro.
Mönkkönen J; Taskinen M; Auriola SO; Urtti A
J Drug Target; 1994; 2(4):299-308. PubMed ID: 7858955
[TBL] [Abstract][Full Text] [Related]
29. New role for an established drug? Bisphosphonates as potential anticancer agents.
Koul HK; Koul S; Meacham RB
Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):111-9. PubMed ID: 21876554
[TBL] [Abstract][Full Text] [Related]
30. Bisphosphonates: Pharmacokinetics, bioavailability, mechanisms of action, clinical applications in children, and effects on tooth development.
Soares AP; do Espírito Santo RF; Line SR; Pinto Md; Santos Pde M; Toralles MB; do Espírito Santo AR
Environ Toxicol Pharmacol; 2016 Mar; 42():212-7. PubMed ID: 26895384
[TBL] [Abstract][Full Text] [Related]
31. [Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates].
Endo Y; Funayama H; Yamaguchi K; Monma Y; Yu Z; Deng X; Oizumi T; Shikama Y; Tanaka Y; Okada S; Kim S; Kiyama T; Bando K; Shima K; Suzuki H; Takahashi T
Yakugaku Zasshi; 2020; 140(1):63-79. PubMed ID: 31902887
[TBL] [Abstract][Full Text] [Related]
32. Physiology of the aging bone and mechanisms of action of bisphosphonates.
Dominguez LJ; Di Bella G; Belvedere M; Barbagallo M
Biogerontology; 2011 Oct; 12(5):397-408. PubMed ID: 21695491
[TBL] [Abstract][Full Text] [Related]
33. Folate-targeted pH-responsive calcium zoledronate nanoscale metal-organic frameworks: Turning a bone antiresorptive agent into an anticancer therapeutic.
Au KM; Satterlee A; Min Y; Tian X; Kim YS; Caster JM; Zhang L; Zhang T; Huang L; Wang AZ
Biomaterials; 2016 Mar; 82():178-93. PubMed ID: 26763733
[TBL] [Abstract][Full Text] [Related]
34. Augmentation of Lipopolysaccharide-Induced Production of IL-1α and IL-1β in Mice Given Intravenous Zoledronate (a Nitrogen-Containing Bisphosphonate) and Its Prevention by Clodronate (a Non-nitrogen-containing Bisphosphonate).
Suzuki H; Bando K; Tada H; Kiyama T; Oizumi T; Funayama H; Sugawara S; Takahashi T; Endo Y
Biol Pharm Bull; 2019; 42(2):164-172. PubMed ID: 30713248
[TBL] [Abstract][Full Text] [Related]
35. Randomized trial comparing efficacies of zoledronate and alendronate for improving bone mineral density and inhibiting bone remodelling in women with post-menopausal osteoporosis.
Tan W; Sun J; Zhou L; Li Y; Wu X
J Clin Pharm Ther; 2016 Oct; 41(5):519-23. PubMed ID: 27440710
[TBL] [Abstract][Full Text] [Related]
36. Antitumor effects of bisphosphonates.
Green JR
Cancer; 2003 Feb; 97(3 Suppl):840-7. PubMed ID: 12548584
[TBL] [Abstract][Full Text] [Related]
37. Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy.
Moosavian SA; Bianconi V; Pirro M; Sahebkar A
Semin Cancer Biol; 2021 Feb; 69():337-348. PubMed ID: 31585213
[TBL] [Abstract][Full Text] [Related]
38. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
Kanakis I; Kousidou OCh; Karamanos NK
In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
[TBL] [Abstract][Full Text] [Related]
39. Nanoparticles for the delivery of zoledronic acid to prostate cancer cells: a comparative analysis through time lapse video-microscopy technique.
Schiraldi C; Zappavigna S; D' Agostino A; Porto S; Gaito O; Lusa S; Lamberti M; De Rosa M; De Rosa G; Caraglia M
Cancer Biol Ther; 2014; 15(11):1524-32. PubMed ID: 25482949
[TBL] [Abstract][Full Text] [Related]
40. Bisphosphonates in the treatment of disorders of mineral metabolism.
Singer FR; Minoofar PN
Adv Endocrinol Metab; 1995; 6():259-88. PubMed ID: 7671099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
